Publikationen, an denen er mitarbeitet Antonio González Martín (10)

2020

  1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530

2019

  1. Corrigendum: Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis (Annals of Oncology (2012) 23 (1130-1137) DOI: 10.1093/annonc/mdr432)

    Annals of Oncology

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  3. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

2016

  1. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052

  2. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

    Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308

  3. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2012

  1. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis

    Annals of Oncology, Vol. 23, Núm. 5, pp. 1130-1137

  2. Progress against solid tumors in danger: The metastatic breast cancer example

    Journal of Clinical Oncology